Analyzing biological characteristics of advanced ALK-rearranged lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

BioEXALK is a prospective study that evaluates the biological characteristics of advanced non-small cell lung cancer (NSCLC) with ALK gene rearrangements, focusing on patients treated with next-generation tyrosine kinase inhibitors (TKIs) in the first line. The study is part of the national EXPLORE ALK cohort and involves collecting tumor tissue and circulating tumor DNA (ctDNA) at diagnosis, during the first tumor evaluation, and at disease progression. Biological analyses will be performed using RNA sequencing on tumor biopsies and next-generation sequencing on blood samples to identify ALK fusion partners and associated mutations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent
* ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods
* Patient included in the EXPLORE ALK study
* Age \> or = 18 years
* Patient treated with first-line new generation ALKi
* Patient agrees to sign an informed consent form and to collect blood samples at inclusion, first tumor evaluation and progression and for whom tumor biopsy at diagnosis is available
* Patient enrolled in the french National Health Insurance program or with a third- party payer

Exclusion Criteria:

* Patients who do not wish to participate in Bioexalk
* Patients under guardianship

Where it's running

• Pneumologie CHU Félix Guyon
  Saint-Denis, La Réunion, France Recruiting
• Centre Hospitalier d'Annecy
  Annecy, France Recruiting
• Centre Hospitalier du Morvan
  Brest, France Recruiting
• Pneumologie CH Métropole Savoie
  Chambéry, France Recruiting
• Centre Hospitalier Intercommunal de Créteil
  Créteil, France Recruiting
• Pneumologie CH Eure-Seine
  Évreux, France Recruiting

Study contacts

• Study coordinator: Florian GUISIER
• Email: florian.guisier@chu-rouen.fr
• Phone: +33 2 32888079

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.